TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.

Publikation

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.

Wissenschaftlicher Artikel/Review - 22.02.2022

Eckardt Julia, Schroeder Christopher, Martus Peter, Armeanu-Ebinger Sorin, Kelemen Olga, Gschwind Axel, Bonzheim Irina, Eigentler Thomas Kurt, Amaral Teresa, Ossowski Stephan, Riess Olaf, Flatz Lukas, Garbe Claus, Forschner Andrea

Zitation

Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Riess O, Flatz L, Garbe C, Forschner A. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. J Cancer Res Clin Oncol 2022; 149:833-840.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Cancer Res Clin Oncol 2022; 149

Veröffentlichungsdatum

22.02.2022

eISSN (Online)

1432-1335

Seiten

833-840

Kurzbeschreibung/Zielsetzung

High tumor mutational burden (TMB) is associated with a favorable outcome in metastatic melanoma patients treated with immune checkpoint inhibitors. However, data are limited in the adjuvant setting. As BRAF mutated patients have an alternative with targeted adjuvant therapy, it is important to identify predictive factors for relapse and recurrence-free survival (RFS) in patients receiving adjuvant anti-PD-1 antibodies.